<div id="readability-page-1"><ul><li>Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside</li></ul><p>Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at  Wedbush upped their Q3 2025 earnings per share estimates for shares of Solid Biosciences  in a research note issued to investors on  Wednesday, August 13th. Wedbush analyst L. Chico now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their prior estimate of ($0.46). Wedbush currently  has a &#34;Outperform&#34; rating and a $14.00 target price on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Wedbush also issued estimates for Solid Biosciences' Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.37) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.58) EPS, FY2028 earnings at ($1.26) EPS and FY2029 earnings at ($0.50) EPS.</p><p>A number of other brokerages also recently issued reports on SLDB. JPMorgan Chase &amp; Co. reduced their price target on Solid Biosciences from $15.00 to $13.00 and set an &#34;overweight&#34; rating on the stock in a report on Thursday. HC Wainwright  reiterated a &#34;buy&#34; rating and set a $20.00 target price on shares of Solid Biosciences in a report on Tuesday, June 17th. Cantor Fitzgerald  set a $16.00 target price on Solid Biosciences and gave the stock an &#34;overweight&#34; rating in a report on Monday, July 21st. Piper Sandler reduced their target price on Solid Biosciences from $20.00 to $17.00 and set an &#34;overweight&#34; rating on the stock in a report on Friday, May 16th. Finally, Citigroup assumed coverage on Solid Biosciences in a report on Thursday, June 26th. They set a &#34;buy&#34; rating and a $14.00 target price on the stock. Ten analysts have rated the stock with a buy rating and two have issued  a strong buy rating to the company's stock. Based on data from MarketBeat.com, Solid Biosciences  has an average rating of &#34;Buy&#34; and an average price target of $15.00.</p><div><p><span></span><span>Get <strong>Solid Biosciences</strong> alerts:</span></p></div><ul><li>Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences</li></ul><p><b>Get Our Latest Stock Report on SLDB</b></p><h2>Solid Biosciences Price Performance</h2><p>Shares of NASDAQ:SLDB opened at $6.17 on Friday. Solid Biosciences has a 1 year low of $2.41 and a 1 year high of $10.37. The company has a market cap of $480.46 million, a PE ratio of -2.20 and a beta of 2.44. The stock's 50-day moving average is $5.59 and its 200 day moving average is $4.41. </p><ul><li>Can Solid Biosciences Challenge Sarepta in the DMD Market?</li></ul><p>Solid Biosciences (NASDAQ:SLDB - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. </p><h2>Institutional Inflows and Outflows</h2><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Legal &amp; General Group Plc boosted its position in shares of  Solid Biosciences by 208.6% during the second quarter. Legal &amp; General Group Plc now owns 6,011 shares of the company's stock valued at $29,000 after buying an additional 4,063 shares during the period.  Ameritas Investment Partners Inc. raised its stake in shares of  Solid Biosciences by 205.5% during the second quarter. Ameritas Investment Partners Inc. now owns 6,740 shares of the company's stock valued at $33,000 after acquiring an additional 4,534 shares in the last quarter.  CWM LLC raised its stake in shares of  Solid Biosciences by 15,188.5% during the first quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares in the last quarter.  Corton Capital Inc. bought a new stake in shares of  Solid Biosciences during the fourth quarter valued at approximately $41,000.  Finally, Pallas Capital Advisors LLC bought a new stake in shares of  Solid Biosciences during the second quarter valued at approximately $54,000. Hedge funds and other institutional investors own  81.46% of the company's stock. </p><h2>Solid Biosciences Company Profile</h2> (Get Free Report)<p>Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Solid Biosciences</li><li>3 REITs to Buy and Hold for the Long Term</li><li>How AEP Became a Critical AI Infrastructure Play</li><li>3 Must-Buy Warren Buffett Stocks for Volatile Times</li><li>How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go?</li><li>Dividend Screener: How to Evaluate Dividend Stocks Before Buying</li><li>Mercury Systems Up 27%: Financials Send Investors a Clear Signal</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9U0xEQg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Solid Biosciences Right Now?</h2><p>Before you consider Solid Biosciences, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.</p><p>While Solid Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SLDB

<p>Wedbush analysts have raised their Q3 2025 earnings estimate for Solid Biosciences (NASDAQ:SLDB) from ($0.46) to ($0.38) per share. They maintain an "Outperform" rating with a target price of $14.00. The consensus for the full-year earnings is ($2.84) per share. Other brokerages have also adjusted their ratings and price targets, with an average target of $15.00. Solid Biosciences shares opened at $6.17, with a market cap of $480.46 million and a PE ratio of -2.20. Institutional investors hold 81.46% of the stock.</p>

Q3 Earnings Estimate for Solid Biosciences Issued By Wedbush